Publication | Open Access

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Neoadjuvant TherapyChemotherapy Versus CetuximabMedicinePathologyHead And Neck CancerHead And Neck Squamous Cell CarcinomaCancer TreatmentNeck OncologyOncologyRadiation Oncology